Anorectal pruritus after intravenous hydrocortisone sodium succinate and sodium phosphate.
A double-blind study demonstrated that single intravenous doses of 100, 200, or 400 mg of hydrocortisone sodium succinate and hydrocortisone sodium phosphate were similar in eosinophil suppression, elevation of glucose, white blood count differential shifts (polymorphonuclear cells, lymphocytes, and monocytes), and urinary excretion of sodium and potassium but not in incidence of side effects. More subjects receiving hydrocortisone sodium phosphate experienced systemic or localized adverse effects than those receiving hydrocortisone sodium succinate. The most common side effect was burning or itching in the anorectal area, which occurred in 16 of 18 subjects medicated with hydrocortisone sodium phosphate, in 1 subject of 6 treated with placebo (saline), and in none who received the sodium succinate. The effect is attributed to the phosphate steroid and appears to last as long as it takes to convert to cortisol.
D000328:Adult; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000009:adverse effects*; D007275:Injections, Intravenous; D008297:Male; D010710:Phosphates / Q000008:administration & dosage / Q000009:adverse effects*; D010919:Placebos; D011538:Pruritus Ani / Q000139:chemically induced*; D013386:Succinates / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D010710:Phosphates; D010919:Placebos; D013386:Succinates; D006854:Hydrocortisone